NASDAQ: CABRCaring Brands Inc Stock
$1.00-0.39 (-28.06%)
Updated Nov 14, 2025
CABR Price
$1.00
Fair Value Price
N/A
Market Cap
$14.74M
52 Week Low
$0.75
52 Week High
$3.20
P/E
N/A
P/B
5.67x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.22
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CABR Overview
Caring Brands, Inc., a wellness consumer products company, provides over-the-counter and cosmetic consumer products. It offers a range of products, such as hair loss treatments, Eczema and Psoriasis Treatments, vitiligo solutions, Jellyfish sting protective suncare line, and women's sexual wellness products that cater to health and wellness needs. The company was incorporated in 2020 and is based in Jupiter, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CABR's potential to beat the market
- CABR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
CABR
RankedUnranked of 58
RankedUnranked of 58
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $45.98 | A | |
| $30.49 | A | |
| $11.64 | A |
Be the first to know about important CABR news, forecast changes, insider trades & much more!
CABR News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CABR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CABR is poor value based on its book value relative to its share price (5.67x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.17x)
P/B vs Industry Valuation
CABR's short-term liabilities ($570.21k) exceed its short-term assets ($45.99k)
Short-term Liabilities Financials
CABR's short-term assets ($45.99k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more CABR due diligence checks available for Premium users.
Valuation
CABR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.67x
Industry
2.17x
CABR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CABR's financial health
Profit margin
Revenue
$740.0
Net Income
-$1.0M
Profit Margin
-137,671.4%
Assets to liabilities
Assets
$3.2M
Liabilities
$572.1k
Debt to equity
0.22
CABR's short-term liabilities ($570.21k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CABR's short-term assets ($45.99k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CABR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$180.8k
Investing
$0.0
Financing
$123.0k
CABR vs Pharmaceutical Stocks
Caring Brands Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.